Meeting
2015 ASCO Annual Meeting
A phase I study of gemcitabine and bendamustine in relapsed/refractory Hodgkin's lymphoma.
Authors
Jonathon Brett Cohen
Emory University - Winship Cancer Institute, Atlanta, GA
Jonathon Brett Cohen , Lai Wei , Kami J. Maddocks , Leonard T. Heffner , Amelia A. Langston , Christopher Flowers , Steven M Devine , Kristie A. Blum
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lymphoma and Plasma Cell Disorders
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Lymphoma
Clinical Trial Registration Number
NCT01535924
Citation
J Clin Oncol 33, 2015 (suppl; abstr 8534)
DOI
10.1200/jco.2015.33.15_suppl.8534
Abstract #
8534
Poster Bd #
351
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Phase 1 trial of brentuximab vedotin in combination with gemcitabine for pediatric and young adult patients with relapsed or refractory Hodgkin lymphoma, a Children’s Oncology Group report.
First Author: Peter D. Cole
Poster
2015 ASCO Annual Meeting
A phase I study combining bendamustine with rituximab, etoposide and carboplatin (TREC) in patients with aggressive relapsed or refractory lymphoma.
First Author: L. Elizabeth Budde
Poster
2015 ASCO Annual Meeting
A phase I trial of lenalidomide maintenance after autologous stem cell transplant (ASCT) in patients with high-risk relapsed/refractory lymphomas.
First Author: Jakub Svoboda
Poster
2023 ASCO Annual Meeting
Phase 1 studies of D07001-F4 and D07001-softgel capsule: Oral metronomic gemcitabine in subjects with advanced solid tumors.
First Author: Chia-Chi Lin